By: Manoah Kikekon
![]() |
| ACPN National Chairman, Pharm. Ambrose Igwekamma Ezeh |
The Association of Community Pharmacists of Nigeria (ACPN) has handed the Chairman of the Edo State Consumer Protection Committee, Mr. Osaro Culture Iyamu, a strict 24-hour deadline to produce regulatory proof backing his reported claim that the antimalarial medicine Camosunate is prohibited in Nigeria, or face immediate legal action.
In a strongly worded press statement jointly signed by ACPN National Chairman, Pharm. Ambrose Igwekamma Ezeh, MAW, and National Secretary, Obigariel Ikwu, the national pharmacy body condemned what it termed "regulatory overreach, unsubstantiated pharmaceutical claims, and questionable enforcement practices" by the state committee.
While reaffirming its support for efforts to eliminate counterfeit, substandard, and expired medicines across Nigeria, ACPN maintained that enforcement operations must be anchored in verifiable facts and statutory law rather than personal opinion.
"A verification of the National Agency for Food and Drug Administration and Control (NAFDAC) official Greenbook identifies Camosunate Children Powder, Registration Number 04-7908, manufactured by Front Pharmaceuticals PLC and marketed by Geneith Pharmaceuticals Limited, as an active registered medicinal product," the association stated.
According to ACPN, official NAFDAC records show the product's registration was approved on November 26, 2025, and remains valid until November 25, 2030. Describing this status as an official regulatory record rather than industry speculation, the association challenged Iyamu to publish an authentic NAFDAC prohibition, suspension, withdrawal, or cancellation notice within 24 hours.
"Failure to provide verifiable evidence within the stipulated period must be followed by an immediate public retraction and apology," the statement warned, adding that the body would pursue legal remedies against demonstrably false statements damaging to registered products and licensed practitioners.
The pharmacists' body also faulted a recent enforcement operation carried out at ALSO CARE Pharmacy in the Evbuodia community along Airport Road, Benin City, alongside public allegations leveled against the outlet.
ACPN demanded full transparency regarding the exact items allegedly confiscated, their NAFDAC registration details, and independent laboratory or regulatory proof confirming they were fake or banned insisting that no licensed pharmacy should face public condemnation based on unverified assertions.
Citing specific federal statutes, ACPN argued that a general consumer protection committee lacks the automatic legal authority to inspect or regulate pharmaceutical premises:
Pharmacy Council of Nigeria (Establishment) Act 2022 (Sections 22, 31, and 32): Reserves pharmaceutical premises registration, inspection, and enforcement strictly for designated Pharmaceutical Inspection Officers.
Counterfeit and Fake Drugs and Unwholesome Processed Foods Act, Cap C34 (Sections 7 and 8): Governs the legal constitution and ministerial appointment of State Task Forces.
NAFDAC Act, Cap N1 (Section 5): Vests primary statutory authority for regulating medicinal products in NAFDAC.
Consequently, ACPN issued a six-point demand requiring Iyamu and the Edo State Government to:
1. Produce authentic NAFDAC documentation validating the alleged Camosunate ban within 24 hours.
2. Issue an immediate public retraction and apology if no proof exists.
3. Disclose the legal instrument establishing the Edo State Consumer Protection Committee.
4. Provide proof of any Federal Ministerial approval constituting the committee as a valid State Task Force under Section 7 of the Counterfeit and Fake Drugs Act.
5. Immediately halt unauthorized pharmaceutical enforcement operations.
6. Respect the constitutional and statutory mandates of NAFDAC and the Pharmacy Council of Nigeria (PCN).
Appealing directly to Edo State Governor, Senator Monday Okpebholo, ACPN urged swift executive intervention to enforce institutional accountability and prevent jurisdictional conflicts capable of eroding public trust in the state's healthcare system.
"Consumer protection must not become a justification for misinformation, administrative arbitrariness, or regulatory intimidation. Public officials must be accountable for their statements, regulatory authority must be established by law, and professional pharmacy practice must be protected within the same legal framework," the association concluded.
